The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism

American Journal of Sports Medicine

Volumn 28, Issue 3, 2000, Pages 364-369

  Williams III, Riley J ^a,b   Attia, Erik ^b   Wickiewicz, Thomas L ^b   Hannafin, Jo A ^b  

^a New York Hospital ^*  (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN;

ANIMAL CELL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BONE MATRIX; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOG; FIBROBLAST; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEOGLYCAN SYNTHESIS; TENDINITIS; TENDON RUPTURE;

EID: 0034042536     PISSN: 03635465     EISSN: None     Source Type: Journal    
DOI: 10.1177/03635465000280031401     Document Type: Article

References (28)

1. Arky R: Physicians' Desk Reference. 51st edition. Montvale, NJ, Medical Economics Data Production Company, 1997
2. Bailey RR, Kirk JA, Peddle BA: Norfloxacin-induced induced rheumatic disease. N Z Med J 96: 590, 1983
3. Ball P: Ciprofloxacin: An overview of adverse experiences. J Antimicrob Chemother 18: 187-193, 1986
4. Bergeron MG: The pharmacokinetics and tissue penetration of the fluoroquinolones. Clin Invest Med 12: 20-27, 1989
5. Burkhardt JE, Forster C, Lozo E, et al: Immunohistochemistry of articular cartilage from immature beagle dogs dosed with difloxacin. Toxicol Pathol 25: 475-480, 1997
6. Burkhardt JE, Hill MM, Lamar CH, et al: Effects of difloxacin on the metabolism of glycosaminoglycans and collagen in organ cultures of articular cartilage. Fundam Appl Toxicol 20: 257-263, 1993
7. Crump B, Wise R, Dent J: Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother 24: 784-786, 1983
8. de la Garza Estrada VA, Vazquez Caballero R, Camacho Caranza JL: Achilles tendon rupture and fluoroquinolones use: Report of two cases. Arch Med Res 28: 429-430, 1997
9. Huston KA: Achilles tendinitis and tendon rupture due to fluoroquinolone antibiotics [letter]. N Eng J Med 331: 748, 1994
10. Jorgensen C, Anaya JM, Didry C, et al: Arthropathies et tendinopathie achilleenne induites par la pefloxacine. A propos d'une observation. Rev Rhum Mal Osteoartic 58: 623-625, 1991
11. Kashida Y, Kato M: Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: Comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds. Antimicrob Agents Chemother 41: 2389-2393, 1997
12. Lee WT, Collins JF: Ciprofloxacin associated bilateral achilles tendon rupture. Aust N Z J Med 22: 500, 1992
13. MacGowan AP, White LO, Brown NM, et al: Serum ciprofloxacin concentrations in patients with severe sepsis being treated with ciprofloxacin 200 mg i.v. bd irrespective of renal function. J Antimicrobial Chemother 33: 1051-1054, 1994
14. Madu AA, Mayers M, Parkins R, et al: Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. Exp Eye Res 63: 129-136, 1996
15. McGarvey WC, Singh D, Trevino SG: Partial Achilles tendon ruptures associated with fluoroquinolone antibiotics: A case report and literature review. Foot Ankle Int 17: 496-498, 1996
16. Mont MA, Mathur SK, Frondoza CG, et al: The effects of ciprofloxacin on human chondrocytes in cell culture. Infection 24: 151-155, 1996
17. Movin TGA, Gad A, Guntner P, et al: Pathology of achilles tendon in association with ciprofloxacin treatment. Foot Ankle Int 18: 297-299, 1997
18. Murrell GA, Jang D, Williams RJ: Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 206: 15-21, 1995
19. Murrell GAC, Doland MM, Jang D, et al: Nitric oxide: An important articular free radical. J Bone Joint Surg 78A: 265-274, 1996
20. Naber KG, Sorgel F, Kinzig M, et al: Penetration of ciprofloxacin into prostatic fluid, ejaculate and seminal fluid in volunteers after an oral dose of 750 mg. J Urol 150: 1718-1721, 1993
21. Ribard P, Audisio F, Kahh M-F, et al: Seven achilles tendinitis including 3 complicated by rupture during fluoroquinolone therapy. J Rheumatol 19: 1479-1481, 1992
22. Royer RJ, Pierfitte C, Netter P: Features of tendon disorders with fluoroquinolones. Therapie 49: 75-76, 1994
23. Shah A, Lettieri J, Kaiser L, et al: Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily. J Antimicrobial Chemother 33: 795-801, 1994
24. Szarfman A, Chen M, Blum M: More on fluoroquinolone antibiotics and tendon rupture [letter]. N Engl J Med 332: 193, 1995
25. Weidekamm E, Portmann R: Penetration of fleroxacin into body tissues and fluids. Am J Med 22: 75S-80S, 1993
26. Williams RJ III, Smith RL, Schurman DJ: Purified staphylococcal culture medium stimulates neutral metalloprotease secretion from human articular cartilage. J Orthop Res 9: 258-265, 1991
27. Zabraniecki L, Negrier I, Vergne P, et al: Fluoroquinolone induced tendinopathy: Report of 6 cases. J Rheumatol 23: 516-520, 1996
28. Zhao X, Xu C, Domagala J, et al: DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistance. Proc Natl Acad Sci USA 94: 13991-13996, 1997